The FDA has approved imlunestrant for the treatment of patients with ESR1-mutated ER+, HER2- metastatic breast cancer.

Caleb Raine, PA-C explains what BCMA is and why it is a common bispecific antibody target in multiple myeloma.

The NCCN has added revumenib (Revuforj) to its guidelines for the treatment of patients with relapsed or refractory acute ...

Pediatric oncology is defined not only by advanced treatments but also by the depth of support provided to patients and families, according to Scott C. Borinstein, MD, PhD, medical director of ...

Specialized palliative medicine and supportive oncology advanced practice providers help create a personalized treatment experience for patients. A cancer diagnosis can bring an avalanche of ...

Subcutaneous pembrolizumab has been approved across all indications, cutting chair and administration times with a median ...